Scientific community is striving to understand the role of heterocycles and fused
heterocycles in drug discovery programme due to its impact on multi-drug resistance (MDR)
of anticancer drugs. Architecting of various scaffolds for cancer treatment has become
gradually increased in many years. Till now there is no treatment which is so proficient that
it can cure the cancer from the roots. Hence, it is very necessary to design novel anticancer
agents with minimum side effects. Synthesis of hybrids from natural leads is one of the rationale
approaches in medicinal chemistry. It remains a big challenge to invent new efficient
drugs to beat cancer. The design and synthesis of fused molecules as anticancer agents is one
of the great innovations of modern era. In drug discovery archetype, a variety of heterocycles
have been considered for the development of novel lead compounds. This article presents
some recent advancements in the field of anticancer heterocyclic agents all around the world
and also attracted the structure activity relationship along with the structure of the most
promising molecules along with IC50 values against various human cancer cell lines.
Keywords: N-Heterocycles, Cytotoxic Agents, Fusion, Natural leads, IC50, Oxadiazoles.
Rights & PermissionsPrintExport